LARIMAR THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-52.0M | $-57.9M | $-74.3M | $-36.5M | $-14.0M | $-13.9M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $188.0K | $212.0K | $70.0K | $16.0K | $12.0K | $11.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $8.3M | $10.1M | $8.6M | $1.6M | — | — |
| Net Cash from Operating Activities | $-43.8M | $-52.0M | $-59.6M | $-28.2M | $-15.0M | $-13.6M |
| Investing Activities | ||||||
| Capital Expenditures | $55.0K | $660.0K | $595.0K | $58.0K | $17.0K | $2.0K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $35.6M | $51.4M | — | — | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $16.6M | $-2.7M | — | — | — | — |
| Net Change in Cash | $8.4M | $-3.2M | $-22.5M | $22.6M | $25.6M | $8.5M |
| Free Cash Flow | $-43.8M | $-52.6M | $-60.1M | $-28.3M | $-15.0M | $-13.6M |